Home
Highly Potent Active Pharmaceutical Ingredients
13 May - 14 May 2019
Highly Potent Active Pharmaceutical Ingredients

SAE Media Group is delighted to announce its 3rd Annual Highly Potent Active Pharmaceutical Ingredients conference coming to London on the 13th-14th May 2019.

The HPAPI global market has developed rapidly in the past year and is continuing to expand into the future, with over a quarter of drugs in development worldwide being classified as highly potent. As a result, there is a growing demand for both pharmaceutical and contracted manufacturers to adapt to the evolving HPAPI landscape.

The event will explore current market trends, challenges of correctly assessing hazard, the use of innovative containment solutions to minimize risk and advanced manufacturing processes. In addition, the conference aims to guide attendees through novel regulatory updates for each stage of HPAPI development.

Attend this conference and join our networking platform for industry professionals to provide you with the expertise to overcome the challenges of the HPAPI industry.

 

FEATURED SPEAKERS

 Mr Justin Mason-Home

Mr Justin Mason-Home

Director, HPAPI Project Services Limited
Dr Thomas Nittoli

Dr Thomas Nittoli

Director, Regeneron Inc
Mr Peter Marshall

Mr Peter Marshall

Associate Engineer Director, AstraZeneca

Mr Justin Mason-Home

Director, HPAPI Project Services Limited
 Mr Justin Mason-Home

Justin Mason-Home is an organic chemist with extensive health, safety, environmental and chemical engineering experience in senior technical, legal and commercial aspects of the biopharmaceutical, industries. He has held senior positions and worked globally in potent biopharmaceutical occupational health and safety global environmental consulting, board level positions in a biotechnology company and corporate environmental management. Mr Mason-Home specialises in technical complex and strategic projects, including unique experience in managing sensitive highly potent and toxic biopharmaceutical compound matters.

David OConnell

Director Scientific Affairs, PCI Pharma Services
David OConnell

David O’Connell is the Director of Scientific Affairs at PCI Pharma Services, an integrated full service provider expertly delivering a seamless transition from development to commercialization. After graduating from Glasgow Caledonian University with a Bachelor of Science degree in applied bioscience David spent seven years as a Supervisory Scientist working for Aptuit in Edinburgh before moving to Penn Pharma as Head of Formulation Development in 2009. Here he played a vital part in the design of the potent Contained Manufacturing Facility (CMF), which won the ISPE Facility of the Year award for Facility Integration (2014). In 2013 David took on the role of Director, Pharmaceutical Development at the PCI site in Tredegar and in 2017 became PCIs Director of Scientific Affairs.

Dr Ildiko Ziegler

Distinguished Validation Expert, Gedeon Richter Plc.
Dr Ildiko Ziegler

Dr. Ildiko Ziegler has been a professional at Gedeon Richter for 15 years and leading different projects in her field for 5 years. She has been a distinguished validation expert since Jan 2014, specialised for cleaning validation and quality risk assessment in the pharma industry. Ildiko obtained M.Sc. in chemical engineering at the Budapest University of Technology and Economics (BUTE) in 1996. She recieved licentiate degree at the Luleå University of Technology (Sweden) in 2000. She defended Ph. D. at the BUTE in 2000 and obtained the Géza Schay Award for the achievments in the field of physical and theoretical chemistry.

Dr Jack Brown

Senior Research Fellow, Boehringer Ingelheim Pharmaceuticals, Inc.
Dr Jack Brown

Senior Research Fellow; Chemical Development, Boehringer Ingelheim
Pharmaceuticals, Inc. 7/18- present. responsible for the scale-up of process,
from laboratory into the kilo lab to the pilot plant. Safe execution of
processes in the kilo lab and pilot plant. Oversee process safety for Chemical
Development.

Dr Olindo Lazzaro

Director, Global EHS Technical Operations, AbbVie
Dr Olindo Lazzaro

Olindo Lazzaro is Director, Global EHS Technical Operations at AbbVie, Responsible for Global EHS Technical Centers of Excellence at AbbVie supporting both R&D and Manufacturing. Key areas of as follows: Process Safety Management, Loss Prevention and Fire Protection, OH/Containment, Chemical Safety and GHS, PiE, Green Chemistry/Ecoefficiency, N2/Inert gas handling, EHS New Product Introduction and EHS Technical Transfer.
Also responsible of AbbVie Environmental and OH Labs ((both ISO 17025 accredited). Lead for Prevention of Catastrophic Incidents (PCI) Strategy at AbbVie. EHS Approver for AbbVie Engineering Standards. Champion of Manufacturing Containment Capital Improvement Long Plan, OH/Containment Engineering Community of Practice and of the AbbVie Pharma In the Environment (PiE) team. He is EHS representative in the Abbvie Operations Pipeline Teams.

Dr Thomas Adam

Head of Global Quality Assurance Chemical APIs, Bayer
Dr Thomas Adam

Thomas Adam studied Chemistry at the University in Saarbruecken and Mainz, Germany. After post-doc at Novartis, Switzerland, he joined Bayer AG. He worked in different Q-functions. Since 2011 he is Head of GQA-Chemical APIs within Chemical Development Department at Bayer AG and responsible for the release of APIs for clinical trials, Qualification,Validation and Supplier Qualification.

Dr Thomas Nittoli

Director, Regeneron Inc
Dr Thomas Nittoli


Tom Nittoli has over 20 years of experience in the pharmaceutical industry and is currently Director of R&D Chemistry. Tom joined Regeneron in 2010 to advance conjugated antibodies and proteins from discovery to development. Since joining Regeneron, he has developed a variety of small molecules for protein conjugation, lead diverse teams of discovery ADC scientists, and lead cGMP synthesis and conjugation campaigns.
Prior to Regeneron, Tom held positions at Pfizer, Wyeth, and CIBA-Giegy. He holds a PhD from the department of chemistry SUNY Stony Brook and was a post-doctoral fellow at the University of Pennsylvania.
 

Dr Ulrich Ruemenapp

Head of Launch Preparation and Coordination, Bayer Pharma
Dr Ulrich Ruemenapp

Dr. Rümenapp is based in Wuppertal, Germany and working within the Product Supply Pharmaceuticals, Biological Development organization, where he is responsible for the transfer of Bayer’s pipeline candidates (antibodies and antibody-drug-conjugates) to external manufacturing partners and regulatory submission and launch preparations.

Prior to working in Development, Dr. Rümenapp was Head of Projects in Product Supply Biotech at Bayer, where he was responsible for contract manufacturing partnerships in the field of biotechnological drug substances and drug products and interdisciplinary project management with the goal to ensure market supply.

Before it was acquired by Bayer, Dr. Rümenapp hold a similar position at Schering AG, and before that, he worked in the Production & Logistics department of Schering, where he was responsible for production aspects of in- and out-licensing deals, due diligences, and product acquisitions of small molecule products and biologics.

Dr. Rümenapp studied chemistry and holds a Ph.D. in biosciences. He worked several years in academic research in the field of signal transduction and as an assistant teacher in the field of general pharmacology.

To correspond with Dr. Rümenapp, please contact him at: ulrich.ruemenapp@bayer.com
 

Dr. Andrew Kyle

R&D Senior Chemist, SK Biotek
Dr. Andrew Kyle

Andrew Kyle is a Senior Chemist within the R&D group at SK biotek in Swords, Dublin. His main focus is in HPAPI products, supporting process development and optimisation to facilitate the technical transfer of scalable synthetic routes to the manufacturing plant. Andrew holds a DPhil degree in Organic Chemistry from the University of Oxford and has previously held the position of Chemistry Team Leader at Abzena, gaining extensive expertise in early stage antibody drug-conjugate design and development.

 

 


 

Fabio Zenobi

EHS Director, BSP Pharmaceuticals S.p.A.
Fabio  Zenobi

EHS Director, BSP Pharmaceuticals S.p.A.
Fabio is responsible of Environment, Health and Safety at BSP Pharmaceuticals S.p.A., Latina Italy, a Contract Development and Manufacturing Organization focused on anticancer product, small molecules and ADC compounds. He is a Pharmaceutical Chemist and has over 20 years of experience in pharmaceutical industries as Serono, Bristol-Myers Squibb and Intervet, in Manufacturing, Quality Assurance, Technical Operations and EHS.

Mike Perry

Director, Pharmadagio Limited
Mike Perry

Mike Perry is an independent occupational hygiene consultant and director of Pharmadagio Limited. His career within the field of potent compound safety began in 2007 when he joined the European branch of SafeBridge Consultants. Working with recognised industry experts, Mike developed a wealth of knowledge and practical experience, leading to the formation of his own consultancy in 2016. His company continues to gain presence through the sharing, application and further development of his expertise through all stages of the drug development cycle, particularly with respect to pharmaceutical exposure control and assessment strategies, containment performance verification and ongoing development of procedures for the optimisation of specialist engineering controls.
 

Mr Jeff Parry

Senior Formulation Scientist, Astrazeneca
Mr Jeff Parry

After graduating, Jeff Parry spent 5 years as an industrial hygienist before joining Astrazeneca as a First Line Manager in the Tablets Pilot Plant at Macclesfield. During the following 18 years, he has worked within various Astrazeneca pilot plants producing both sterile parenteral, and oral solid dosage forms.
Most recently, he has been responsible for representing R&D in the refurbishment of a dedicated building for the formulation science department at Macclesfield – using this opportunity to change the ways of working with high potent API’s, from containing people to working with contained equipment.
 

Mr Martin Axon

Principal Occupational Hygienist, SafeBridge Europe Ltd
Mr Martin Axon

Martin commenced his career working as analytical chemist for a multinational pharmaceutical company; there he qualified as an occupational hygienist which he put into practice at primary and secondary manufacturing at several international sites.  Following a break from the pharmaceutical industry (5 years working in academia), he joined SafeBridge in 2005.  He is now responsible for the SafeBridge Certification programme in Europe; he provides advice on the safe handling of potent APIs to clients throughout Europe.

Mr Nigel Saunders

SME Containment, GSK
Mr Nigel Saunders

Qualified as a Mechanical and Electrical Engineer, after an early career specialising in mechanical handling and high-speed filling and packaging equipment Nigel joined GlaxoSmithKline 25 years ago working in primary API manufacturing. Responsible for project managing the installation of API manufacturing plant specialising in containment system. 10 years ago, Nigel transferred into a central role in Engineering & EHS. He is the Global Subject Matter Expert on containment system and materials handling for the Pharma, Consumer Health and Biopharm Supply Chains and works closely with R&D on technical transfer of HPAPI’s into GSK manufacturing and CMO’s.

Mr Peter Marshall

Associate Engineer Director, AstraZeneca
Mr Peter Marshall

Trained as a Biochemical Engineer at UCL, Peter has worked for ICI/Zeneca/AstraZeneca for 33 years, with 25 years working with high hazard chemicals.
Responsibilities include global Subject Matter Expert for containment systems, Technical Lead for multiple international OSD developments, and support to multiple emerging market CMOs in areas of technical transfer and worker safety.
Co-chair ISPE Containment CoP Committee 2006-9, current member.
Member of Author teams for
‘SMEPAC’ containment system testing GPG (1st and 2nd Edns),
Cross Contamination Baseline guide (RiskMAPP) (1st/2nd Edns)
OSD Baseline Guide 3rd Edition.
 

Ms Ester Lovsin Barle

PhD, MScTox, ERT, Lonza
Ms Ester Lovsin Barle

Ester Lovsin Barle, DVM, MSc, PhD, MScTox is the Head of Corporate Toxicology at the at Lonza and responsible for Health topics at the Corporate Lonza EHS. Previously she has been the Head of Health Hazard Assessment in Novartis Global HSE & BCM. Her responsibilities include scientific development and cross-organizational implementation of health based exposure limits (HBEL), compiling global policy on occupational toxicology and patient safety related process in support of manufacturing in Lonza globally, as well as global implementation of safe handling of chemicals. She is leading the Lonza Global biosafety network. She received her PhD in veterinary sciences from University of Ljubljana, Slovenia and a second masters degree in toxicology and risk assessment from Medical University in Vienna.
Dr. Lovsin Barle is author/co-author of over 60 publications including peer-reviewed articles and book chapters. She is a member of several pharma industry and toxicological associations and boards and has served as the president of the Slovenian Society of toxicology. She lectures at several universities.

 

sponsors

Conference agenda

clock

8:30

Registration & Coffee

clock

8:45

Strategic HPAPI Project Considerations

Justin Mason-Home

Justin Mason-Home, Director, HPAPI Project Services Limited

clock

9:15

Hazard Assessment – It All Starts with the Hazard

Justin Mason-Home

Justin Mason-Home, Director, HPAPI Project Services Limited

clock

9:45

Process is Primary

clock

10:10

Real Risk Assessment – Risk to Product and Risk to Workers

Justin Mason-Home

Justin Mason-Home, Director, HPAPI Project Services Limited

clock

10:30

Morning Coffee

clock

10:50

Facility Design Features

Justin Mason-Home

Justin Mason-Home, Director, HPAPI Project Services Limited

clock

11:20

Containment for Higher Risk Activities and Control for Lower Risk Activities

Justin Mason-Home

Justin Mason-Home, Director, HPAPI Project Services Limited

clock

11:40

Verification of Control/Containment Performance

Justin Mason-Home

Justin Mason-Home, Director, HPAPI Project Services Limited

clock

12:00

Occupational Health and Safety Management Systems

Justin Mason-Home

Justin Mason-Home, Director, HPAPI Project Services Limited

clock

12:30

Workshop Leaders's Closing Remarks

Justin Mason-Home

Justin Mason-Home, Director, HPAPI Project Services Limited

clock

13:30

Registration and Introduction

Mike Perry

Mike Perry, Director, Pharmadagio Limited

clock

13:40

Understanding containment performance targets and method sensitivity

Mike Perry

Mike Perry, Director, Pharmadagio Limited

clock

14:00

Understanding the role of personal sampling and static sampling

Mike Perry

Mike Perry, Director, Pharmadagio Limited

clock

14:30

Applying an appropriate statistical tool to small data sets

Mike Perry

Mike Perry, Director, Pharmadagio Limited

 

 

clock

15:00

Afternoon Tea

clock

15:30

Sampling strategy options and development of a suitable sampling plan

Mike Perry

Mike Perry, Director, Pharmadagio Limited

clock

16:00

Communication with the laboratory, storage and shipping requirements

Mike Perry

Mike Perry, Director, Pharmadagio Limited

clock

16:30

Workshop Leader's Closing Remarks

Mike Perry

Mike Perry, Director, Pharmadagio Limited

clock

8:30

Registration & Coffee

clock

9:00

Chairman's Opening Remarks

Mr Justin Mason-Home, Director, HPAPI Project Services Limited

clock

9:10

Practical Elements in Rolling Out HPAPI Projects

  • Hazard assessment and strategic business matters
  • Proper risk assessment
  • Containment and control "hardware" and "software"
  • Dealing with engineers and equipment vendors
  • Verification of a safe working environment
     
  • Mr Justin Mason-Home, Director, HPAPI Project Services Limited

    clock

    9:50

    Occupational Exposure Limits - how are they derived and what do they say?

    Ms Ester Lovsin Barle, PhD, MScTox, ERT, Lonza

  • Do you have a highly potent drug and don’t know what it means for workers?
  • What goes into the OEL?
  • What are the limits of the OEL?
  • clock

    10:30

    Morning Coffee

    clock

    11:00

    Manufacturing of Oncological Drug Products & Drug Substance by a CDMO

    Fabio Zenobi, EHS Director, BSP Pharmaceuticals S.p.A.

    • New Product Introduction
    • Case Study: ADC Manufacturing
    • Waste & Wastewater treatment
    • Project phase out
    clock

    11:40

    Demonstrating that Exposure Controls are Effective

    Mr Martin Axon, Principal Occupational Hygienist, SafeBridge Europe Ltd

  •   Examples of control devices and their performance.
  • Where does the data come from?
  • ADCs – can we really measure nanogramme concentrations?

     

  • clock

    12:20

    Networking Lunch

    clock

    13:20

    OH/Containment Strategy and NPI at AbbVie

    Dr Olindo Lazzaro, Director, Global EHS Technical Operations, AbbVie

  • OH/ Containment improvement Targets and LRP
  • OH exposure risk assessment and Improvement projects
  • NPI and Tech Transfer
  • Team Approach - Community of Practice
  • OH Metrics  
  • clock

    14:00

    Internal Procedure Guide in Handling High Potent Compounds

    Dr Thomas Adam, Head of Global Quality Assurance Chemical APIs, Bayer

     

  • Bayer quality organisation guidelines
  • Internal procedures to minimise the risk of handling HPAPIs to workers
  •  Deciding the correct control based on a correctly identified hazard

     

     

  • clock

    14:40

    Development and manufacture of HPAPI drug products through the clinical phases from molecule to market

    David OConnell, Director Scientific Affairs, PCI Pharma Services

  • How HPAPIs can be developed into suitable drug dosage forms
  • Strategies to adhere to the highest quality standards
  • Complexities at each stage of the development cycle from FiM studies to global supply
     
  • clock

    15:20

    Afternoon Tea

    clock

    15:50

    Risk Assessment of Highly Potent APIs: Cross-Contamination and Transportation Parameters

    Dr Ildiko Ziegler, Distinguished Validation Expert, Gedeon Richter Plc.

  • Guidelines regarding Quality Risk Management
  • Case study 1: technical aspects and complexity in cross contamination risk analysis
  • Case study 2: temperature deviation during transportation
  • clock

    16:30

    Design and Innovation of a New Compound Facility

    Dr Jack Brown, Senior Research Fellow, Boehringer Ingelheim Pharmaceuticals, Inc.

  • Reconstruction guidelines for adapting existing facilities to meet the needs of HPAPIs
  • Ensuring facility reconstruction meets GMPs
  • Additional assets required for HPAPI adaptation
  • Designing controls and training to address worker safety
  • clock

    17:10

    Chair's closing remarks

    Mr Justin Mason-Home, Director, HPAPI Project Services Limited

    clock

    8:30

    Registration & Coffee

    clock

    9:00

    Chairman's Opening Remarks

    Mr Justin Mason-Home, Director, HPAPI Project Services Limited

    clock

    9:10

    Principles of Pharmaceutical Containment in Isolator Designs

    Mr Peter Marshall, Associate Engineer Director, AstraZeneca

    • Innovative solutions to dealing with the increasing toxicity of ADCs
    • Designing single use systems
    • Considerations when choosing between single use Vs traditional use systems
    • Real world examples of single use systems in industry
     

    clock

    9:50

    Antibody Drug Conjugate Manufacturing – Coordination of Linker-payload synthesis and Antibody Conjugation

    Dr Thomas Nittoli, Director, Regeneron Inc

    • Technology transfer
    • Scale-up
    • Qualification
    • ADC Toxicology lot
    • ADC GMP lot
     

    clock

    10:30

    Morning Coffee

    clock

    11:00

    Adaptation of Containment Designs to Cope with the High Demands of HPAPIs

    Mr Jeff Parry, Senior Formulation Scientist, Astrazeneca

    • Overview of up to date containment manuals
    • Containment for HPAPIs with low OELs
    • Challenges of reconstructing new facilities in alignment with GMPs
     

    clock

    11:40

    The Challenges Verifying Containment Performance of a HPAPI OSD Facility

    Mr Nigel Saunders, SME Containment, GSK

    · A real life example of the challenges containment testing presents
    · Strategies used to verify containment performance.
    · The successes, learnings and rewards

     

    clock

    12:20

    Networking Lunch

    clock

    13:20

    Outsourcing Late Stage CMC Development and Bio-Manufacturing for Fast Track Projects with Accelerated Timeline – the Challenges and Needs

    Dr Ulrich Ruemenapp, Head of Launch Preparation and Coordination, Bayer Pharma

    • Drivers for accelerated CMC development
    • Pathways open for expedited regulatory review and approval
    • Considerations for CMC development and regulatory submission
    • Challenges and risks of accelerated projects, especially when outsourcing bio-manufacturing

    clock

    14:00

    Respiratory APIs: Peculiarities of Development and Formulation

    Mike Perry, Director, Pharmadagio Limited

    clock

    14:40

    Panel Discussion: CMO Outsourcing Options and Selection Methodologies

  • Criteria for CMO selection
  • Confidentiality
  •  EHS compliance
  •  Efficiency at every step
  • Dr Ildiko Ziegler, Distinguished Validation Expert, Gedeon Richter Plc.

    Dr Jack Brown, Senior Research Fellow, Boehringer Ingelheim Pharmaceuticals, Inc.

    clock

    15:20

    Afternoon tea

    clock

    15:50

    Operation of a fully integrated & versatile HPAPI manufacturing facility

    Dr. Andrew Kyle, R&D Senior Chemist, SK Biotek

    · HPAPIs - Containment philosophy, infrastructure and safety culture
    · Operation of a dedicated HPAPI process development laboratory
    · A versatile HPAPI facility for a safe and efficient tech-transfer
    · Clinical and commercial manufacture of HPAPIs

     

    clock

    16:30

    Meeting containment performance targets in practice - a three year review of air sampling data’

    clock

    17:10

    Chair's closing remarks

    Mr Justin Mason-Home, Director, HPAPI Project Services Limited


    Director
    HPAPI Project Services Limited
    Director Scientific Affairs
    PCI Pharma Services
    Distinguished Validation Expert
    Gedeon Richter Plc.
    Senior Research Fellow
    Boehringer Ingelheim Pharmaceuticals, Inc.
    Director, Global EHS Technical Operations
    AbbVie
    Head of Global Quality Assurance Chemical APIs
    Bayer
    Director
    Regeneron Inc
    Head of Launch Preparation and Coordination
    Bayer Pharma
    R&D Senior Chemist
    SK Biotek
    EHS Director
    BSP Pharmaceuticals S.p.A.
    Director
    Pharmadagio Limited
    Senior Formulation Scientist
    Astrazeneca
    Principal Occupational Hygienist
    SafeBridge Europe Ltd
    SME Containment
    GSK
    Associate Engineer Director
    AstraZeneca
    PhD, MScTox, ERT
    Lonza

    Sponsors and Exhibitors

    Supporting Media Partners

    Supporters

    HPAPI 2019 Attendees

    Download

    Interview with Dr Ulrich Ruemenapp from Bayer Pharma

    Download

    Interview with Ildikó Ziegler Gedeon Richter

    Download

    2019 HPAPI Chair Letter

    Download

    Interview with Ester Lovsin Barle from Lonza

    Download

    Waste Management for Highly Potent APIs

    Download

    The Manufacturing of Oncological Products by a CDMO

    Download

    Interview with Peter Marshall, AstraZeneca

    Download

    HPAPI Work Shop Programme 15th May

    Download

    HPAPI 2019 Speaker Line-Up

    Download

    HPAPI 2019 Conference Brochure

    Download

    HPAPI 2019 Programme

    Download

    HPAPI Past Attendees

    Download

    HPAPI Info Graphic 2019

    Download

    Sponsors and Exhibitors


    BSP Pharmaceuticals

    Sponsors and Exhibitors
    http://www.bsppharmaceuticals.com

    BSP Pharmaceuticals S.p.A. is a CDMO (Contract Development and Manufacturing Organization), focused on the development and manufacturing of anticancer drugs with High Potency and Cytotoxic characteristic and It is specialized on formulation and manufacturing of Small Molecules and ADC products (Antibody Drug Conjugate). BSP has been at the forefront in the fight against cancer since 2006. Innovation is the hallmark of BSP with investments in new technologies and production methods in a high containment plant. With its state-of-the-art technology and highly skilled personnel, BSP sets out to be a valuable point of reference to serve the principal actors of the pharmaceutical field involved in research on new generation anticancer therapies. BSP clients can avoil of this integrated services: • DEVELOPMENT SERVICES • CLINICAL SUPPLY • COMMERCIAL SUPPLY BSP has been conceived starting from a basic but essential operating requirement: segregate the high potent components from the surrounding and create a system suitable to manage pharmaceutical processes. With this primary idea in mind, layouts, flows of materials and personnel, air flows have been designed to minimize the risk of contamination for the environment, for the employees and for the product that is intended for patients with low level of immune defenses. The Manufacturing plant is located in Italy, 60 kilometers southbound of Rome. A single campus extended to more than 40 acres hosts all the main buildings supporting the capacities to manage a wide range of batch sizes: 2| DEVELOPMENT LABORATORIES 3| CONJUGATION SUITES 6| STERILE SUITES with more than 170 m2 fully dedicated to production anticancer and cytotoxic drugs 1| ORAL DEPARTMENT with multiple lines suitable to manufacture Clinical and Commercial products


    Dec Group

    Sponsors and Exhibitors
    http://

    Leading global provider of powder handling and process containment technologies, Dec Group provides efficient high containment solutions from milligrams to tons and from concept to completion.


    ILC Dover

    Sponsors and Exhibitors
    https://www.ilcdover.com/

    Trusted by major players in HP API & ADC development, Solo bring high performance containment solutions in innovative single use packages. Solo’s solutions include toxin-linker compounding as well as NCE molecule development isolators and now extend to Grade A aseptic fill/finish isolators – all supported by validation documentation and containment performance testing.


    MINAKEM

    Sponsors and Exhibitors
    http://www.minakem.com

    Minakem is a fully integrated CDMO for HPAPIs and ADC drug-linkers thanks to a dedicated site (FDA approved) having more than 40 years’ experience in HPAPIs, state-of-the-art containment systems, capability to handle broad range of chemistry and technologies including preparative-HPLC from grams to hundreds of kg per batch (GMP).


    PCI Pharma Services

    Sponsors and Exhibitors
    http://www.pciservices.com

    PCI Pharma Services is an integrated full service provider, a proven and trusted partner to leading companies in the global healthcare industry. We offer unparalleled expertise and experience in taking compounds from the earliest stages of development through to successful commercialization, delivering speed-to-market and commercial success for our customers. Our core services support each stage of the product lifecycle, including drug development, clinical trial supply, commercial launch and ongoing commercial supply. We partner with clients in providing innovative technologies, flexible solutions, and an integrated supply network supporting lifesaving medicines destined to over 100 countries around the world. We support clients with a dedication to providing the industry’s leading experience, exemplified in our operational flexibility, delivery, and commitment to safety, supported by industry leading technologies and an exemplary quality and regulatory record. This has allowed us to be the partner of choice for leading pharmaceutical companies around the world, operating as a seamless extension of their business.


    SafeBridge

    Sponsors and Exhibitors
    https://www.safebridge.com/

    SafeBridge is a unique team of occupational and environmental toxicologists, industrial hygienists, chemists and safety and environmental professionals with extensive experience inside the pharmaceutical industry. SafeBridge provides professional consulting services and analytical support to clients across the United States and internationally including the United Kingdom, Ireland, continental Europe, and Canada.


    SK Biotek

    Sponsors and Exhibitors
    http://www.skbiotek.ie

    SK biotek and AMPAC Fine Chemicals a team to be reckoned with… SK Biotek (SKBT) and AMPAC Fine Chemicals (AFC) are wholly owned subsidiaries of the South Korean conglomerate SK, a global leader in energy, chemicals and information technology. The partnership between the companies, established in 2018, creates substantial market synergies in the API CDMO space by combining highly complementary assets and expertise of these companies, enabling us to provide the highest quality services to our customers. SKBT has two sites in Korea, an R&D/Manufacturing facility in Daejeon and a large scale manufacturing site in Sejong and a further site in Swords, Co. Dublin, Ireland, which specializes in the supply of clinical and commercial API. The state of the art facility in Swords has been manufacturing API and Intermediates for >50 years. As leaders in operational excellence and continuous improvement and boasting exceptional technical capabilities, Swords Campus provides a strong offering to our customers through scale-up, launch and secure commercial supply of NCEs. Within the general Campus capabilities, we offer access to world-class potent handling capability (down to low nanogram per cubic meter levels) and have a strong material science group on Campus. Our plants in Korea offer cost effective supply of late phase and commercial pharmaceutical API and Intermediates. Our scientists and engineers are leading exponents of continuous manufacturing methodologies (tubular and fixed bed reactions) and have successfully developed processes from low kilograms through to 10s of tonnes. Continuous Flow Processing can offer many advantages over traditional batch processing. It is not just greener, highly efficient and often cost effective, it also provides access to low and high temperature, hazardous, high-pressure and catalytic reactions. AMPAC Fine Chemicals (AFC) became part of the SK family in the mid-2018, expanding the manufacturing footprint to the US. AFC is a custom manufacturer of APIs and Intermediates; we have been solving problems for customers through technology and innovation to reliably deliver quality products for >75 years. With integrated facilities in California, Texas, and Virginia specializing in process development, scale-up, and cGMP compliant production from kilograms to multi-ton quantities, we have developed capabilities that support a wide range of processes and technologies. We are the leading exponent of Simulated Moving Bed technology (SMB) and offer this powerful technology from lab, through pilot to large commercial scale. We have a proven track record in successfully developing processes involving highly energetic chemistry and now offer supply capability for Controlled Substances from our DEA approved facility in Virginia. As part of the SK Family, AMPAC and SK biotek in combination is able to provide our customers a broader portfolio of offerings. With a strong technology toolbox supporting Continuous Processing, highly energetic chemistries, SMB and HPAPI and access to over 1000m³ of global capacity, spread across three continents, we have the capability and capacity to support all your API and Intermediate needs across the full lifecycle. As an SK customer, we commit to work with you and your product as if it were our own; after all, we have been doing it for decades, producing many of the world’s most recognized drugs.

    Media Partners


    Gate2Biotech

    Supporting Media Partners
    http://www.gate2biotech.com

    Gate2Biotech is a portal that unites biotechnological community in Central Europe. It covers all the news in the field of biotechnology. Thanks to the the portal the companies engaged in the field can easily search for research institutions and other partners to solve technical problems they are facing and here they can also present their services offer to potential partners from the Czech Republic and abroad. Gate2Biotech portal serves as a bridge connecting scientific and commercial sector. It incorporates offices and support organizations dedicated to promoting transfer of innovative technologies into a unified communication platform of Czech and international biotechnologies. As a mediator of information it draws attention to biotechnologies and support of their application and transfer into practice. It also functions as a tool for encouraging non-professionals (especially scientists and students) towards innovative business or applied research.

    Media Partners


    PharmaVOICE

    Supporters
    http://www.pharmavoice.com

    PharmaVOICE magazine, and its supporting VIEW publications, provide commentary about the challenges and trends impacting the life-sciences industry, covering a range of issues from molecule through market. PharmaVOICE's more than 41,000 U.S.-based subscribers are also kept abreast of the latest trends through additional media resources, including WebSeminars, Podcasts, Videocasts, and White Papers.

    Copthorne Tara Hotel

    Scarsdale Place
    Kensington
    London W8 5SR
    United Kingdom

    Copthorne Tara Hotel

    The Copthorne Tara Hotel London Kensington is an elegant contemporary four-star hotel in prestigious Kensington, located just a two minutes walk from High Street Kensington underground station, making exploring easy. The hotel offers well-appointed and comfortable guest rooms combining Standard, Superior and Club accommodation. Club rooms offer iconic views over the city and include Club Lounge access for complimentary breakfast and refreshments. Guests can sample the authentic Singaporean, Malaysian and Chinese cuisine at Bugis Street, traditional pub fare at the Brasserie Restaurant & Bar or relax with a delicious drink at West8 Cocktail Lounge & Bar.

    The Copthorne Tara Hotel boasts 745 square meters of flexible meeting space, consisting of the Shannon Suite and the Liffey Suite, ideal for hosting conferences, weddings and social events. Facilities include access to the business centre 24 hours a day, fully equipped fitness room, gift shop, theatre desk and Bureau de Change. With ample onsite parking outside the London congestion charge zone and excellent transport links via Heathrow Airport, the hotel is the perfect location for business or leisure stays. The hotel is within close proximity to the shops of High Street Kensington, Knightsbridge and Westfield London, Olympia Conference Centre, Royal Albert Hall, Kensington Palace and Hyde Park.

     

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download

    Title


    Description

    Download

    Title


    Description


    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SAE Media Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@saemediagroup.com

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    Group Booking

    Please complete the below form and a member of SAE Media Group’s booking team will be in contact within 24 hours

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SAE Media Group

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SAE Media Group , Ground Floor, India House, 45 Curlew Street, London, SE1 2ND, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smgconferences.com Email: events@saemediagroup.com
    Registered in England - SMi Group Ltd trading as SAE Media Group




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.

    Thank you for visiting our event

    If you would like to receive further information about our events, please fill out the information below.

    By ticking above you are consenting to receive information by email from SAE Media Group.
    Full details of our privacy policy can be found here https://www.smgconferences.com/privacy-legals/privacy-policy/.
    Should you wish to update your contact preferences at any time you can contact us at data.privacy@smgconferences.com.
    Should you wish to be removed from any future mailing lists please click on the following link http://www.smgconferences.com/opt-out

    Fill in your details to download the brochure

    By submitting this form you agree to our privacy policy and consent to receiving communications, you may opt out at any time.